P088 Nerve sparing HIFU as primary “focalized” treatment for localized prostate cancer: A single center study of 158 men with 7 years of follow up

2012 ◽  
Vol 11 (5) ◽  
pp. 220-221
Author(s):  
C.J.L. D'Hont ◽  
P. Van Erps ◽  
M. Sorber ◽  
J. Cortvriend ◽  
T. De Backer
2016 ◽  
Vol 26 (9) ◽  
pp. 517-523 ◽  
Author(s):  
L. Hoquetis ◽  
B. Malavaud ◽  
X. Game ◽  
J.B. Beauval ◽  
D. Portalez ◽  
...  

BMC Urology ◽  
2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Giampaolo Bolzicco ◽  
Maria Silvia Favretto ◽  
Ninfa Satariano ◽  
Enrico Scremin ◽  
Carmelo Tambone ◽  
...  

Author(s):  
Justine Huart ◽  
Antoine Bouquegneau ◽  
Laurence Lutteri ◽  
Pauline Erpicum ◽  
Stéphanie Grosch ◽  
...  

Abstract Background Proteinuria has been commonly reported in patients with COVID-19. However, only dipstick tests have been frequently used thus far. Here, the quantification and characterization of proteinuria were investigated and their association with mortality was assessed. Methods This retrospective, observational, single center study included 153 patients, hospitalized with COVID-19 between March 28th and April 30th, 2020, in whom total proteinuria and urinary α1-microglobulin (a marker of tubular injury) were measured. Association with mortality was evaluated, with a follow-up until May 7th, 2020. Results According to the Kidney Disease Improving Global Outcomes staging, 14% (n = 21) of the patients had category 1 proteinuria (< 150 mg/g of urine creatinine), 42% (n = 64) had category 2 (between 150 and 500 mg/g) and 44% (n = 68) had category 3 proteinuria (over 500 mg/g). Urine α1-microglobulin concentration was higher than 15 mg/g in 89% of patients. After a median follow-up of 27 [14;30] days, the mortality rate reached 18%. Total proteinuria and urinary α1-microglobulin were associated with mortality in unadjusted and adjusted models. This association was stronger in subgroups of patients with normal renal function and without a urinary catheter. Conclusions Proteinuria is frequent in patients with COVID-19. Its characterization suggests a tubular origin, with increased urinary α1-microglobulin. Tubular proteinuria was associated with mortality in COVID-19 in our restropective, observational study.


2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
T. Kaleta ◽  
A. Stock ◽  
D. Panayotopoulos ◽  
O. Vonend ◽  
D. Niederacher ◽  
...  

Objective. The purpose of this prospective study was to investigate the predictive value of single prepartum findings combined with serum biomarkers sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) indicating severity of preeclampsia (PE) for occurrence and extent of impaired postpartum kidney function.Study Design. In this prospective, single center study 44 PE patients were compared to 39 healthy controls (similar in age and gestational age with singleton pregnancy) evaluated at time of delivery and at 6 months and 12 months postpartum.pvalues below 0.05 are considered statistically significant.Results. The majority of the PE patients had persistence of proteinuria (>120 mg/L after delivery) 6 months (p=0.02) and 12 months postpartum (p<0.0001) compared to controls. Also reduced GFR (glomerular filtration rate) persisted up to 6 months postpartum in PE patients compared to controls (p<0.001). Prepartum sFlt-1 levels indeed correlated with impaired renal function parameters.Conclusion. A significant proportion of our PE patients had lower GFR levels and persistent proteinuria up to 12 months postpartum. Prepartum sFlt-1 is a trend-setting marker for impaired renal function postpartum, but it is not sufficient enough to predict renal impairment after PE. An evaluation of 24-month follow-up data is scheduled.


Sign in / Sign up

Export Citation Format

Share Document